Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CRVS
CRVS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRVS News
CORVUS PHARMACEUTICALS: OPPENHEIMER INCREASES TARGET PRICE TO $33, UP FROM $32
Mar 13 2026
moomoo
Corvus (CRVS) Q4 2025 Earnings Call Transcript
Mar 13 2026
NASDAQ.COM
Corvus Pharmaceuticals Q4 2025 Earnings Call Insights
Mar 13 2026
seekingalpha
Corvus Pharmaceuticals Q4 Earnings Miss Expectations
Mar 12 2026
seekingalpha
Corvus Pharmaceuticals Set to Announce Q4 Earnings on March 11
Mar 11 2026
seekingalpha
Analysis of Corvus Pharmaceuticals Put Selling
Feb 02 2026
NASDAQ.COM
Momentum Is Beginning for These 3 Fast-Growing Stocks in 2026
Feb 02 2026
Marketbeat
Corvus Pharmaceuticals (CRVS) Stock Soars 211.8% to New All-Time High
Jan 26 2026
Yahoo Finance
Corvus Pharmaceuticals Upsizes Stock Offering to $175 Million for R&D and Working Capital
Jan 22 2026
stocktwits
Corvus Pharmaceuticals Prices $175M Upsized Public Offering to Fund Clinical Trials
Jan 22 2026
seekingalpha
Corvus Pharmaceuticals Prices Upsized Offering of 7.9 Million Shares at $22.15, Raising $175 Million
Jan 22 2026
Yahoo Finance
Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
Jan 21 2026
Benzinga
Corvus Pharmaceuticals Initiates $150 Million Public Offering Amid 8.92% Stock Decline
Jan 21 2026
NASDAQ.COM
U.S. Stocks Plunge as Trump Revives Tariff Threats
Jan 21 2026
stocktwits
Corvus Pharmaceuticals Launches $150 Million Public Offering to Fund Clinical Trials
Jan 21 2026
stocktwits
Corvus Pharmaceuticals Soars 165.96% to $21.41 After Positive Eczema Data, Plans $150M Offering
Jan 21 2026
Fool
Show More News
